GV 2016 GP, L.L.C. 3
3 · Magenta Therapeutics, Inc. · Filed Jun 20, 2018
Insider Transaction Report
Form 3
GV 2016 GP, L.L.C.
10% Owner
Holdings
- (indirect: By GV 2016, L.P.)
Series A Preferred Stock
→ Common Stock (51,626 underlying) - (indirect: By GV 2016, L.P.)
Series B Preferred Stock
→ Common Stock (3,287,511 underlying)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock is convertible into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a 2.58398:1 basis at any time at the holder's election and will automatically convert immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
- [F2]Each share of Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a 2.58398:1 basis at any time at the holder's election and will automatically convert immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- [F3]The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2016 GP, L.P., GV 2016 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc. and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.